论文部分内容阅读
再生障碍性贫血是一种危及生命的血液病,其特点是全血细胞减少和骨髓中无骨髓细胞或骨髓细胞过少。该病可由多种不同病因引起,不同病人发病机制不尽相同。抗胸腺细胞球蛋白(antithymocyteglobulin,ATG)对30～75%的再生障碍性贫血患者有一定疗效。Speck 等报告雄性激素能增强抗淋巴细胞球蛋白或 ATG 的疗效。这一点目前仍有争议。本文试验旨在判定在再生障碍性贫血的治疗中,采用ATG 加雄性激素是否优于单独使用 ATG。作者在121例再生障碍性贫血中,选择53例中～
Aplastic anemia is a life-threatening hematologic disorder characterized by pancytopenia and an absence of bone marrow or bone marrow cells in the bone marrow. The disease can be caused by a variety of different causes, different patient pathogenesis is not the same. Anti-thymocyte globulin (antithymocyteglobulin, ATG) 30 ~ 75% of patients with aplastic anemia have a certain effect. Speck et al reported that androgen can enhance the anti-lymphocyte globulin or ATG efficacy. This point is still controversial. The purpose of this study was to determine whether the use of ATG plus androgen is superior to ATG alone in the treatment of aplastic anemia. In 121 cases of aplastic anemia, 53 cases were selected